Raymond James Financial Services Advisors, Inc. - CIDARA THERAPEUTICS INC ownership

CIDARA THERAPEUTICS INC's ticker is CDTX and the CUSIP is 171757107. A total of 52 filers reported holding CIDARA THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Raymond James Financial Services Advisors, Inc. ownership history of CIDARA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$74,546
+4.4%
79,119
+25.2%
0.00%
Q2 2023$71,424
-19.3%
63,207
-9.3%
0.00%
Q1 2023$88,462
+58.8%
69,655
-5.4%
0.00%
Q4 2022$55,705
-0.5%
73,655
-16.9%
0.00%
Q3 2022$56,000
+33.3%
88,686
+2.2%
0.00%
Q2 2022$42,000
-41.7%
86,739
+0.5%
0.00%
Q1 2022$72,000
-24.2%
86,278
+15.0%
0.00%
Q4 2021$95,000
-52.5%
75,035
-16.0%
0.00%
Q3 2021$200,000
+4.7%
89,342
-5.3%
0.00%
Q2 2021$191,000
-17.3%
94,339
+8.8%
0.00%
-100.0%
Q1 2021$231,000
+29.1%
86,704
-3.1%
0.00%
Q4 2020$179,000
-36.1%
89,479
-8.8%
0.00%
-100.0%
Q3 2020$280,000
-25.5%
98,080
-3.9%
0.00%0.0%
Q2 2020$376,000
-21.2%
102,025
-17.9%
0.00%
-50.0%
Q4 2019$477,000
+132.7%
124,223
+21.0%
0.00%
+100.0%
Q3 2019$205,000
-4.2%
102,641
-19.5%
0.00%0.0%
Q2 2019$214,000
-44.4%
127,520
-12.2%
0.00%
-50.0%
Q1 2019$385,000
-39.3%
145,222
-46.2%
0.00%
-33.3%
Q4 2018$634,000
-32.2%
269,872
+27.0%
0.00%
-25.0%
Q3 2018$935,000
+6.6%
212,566
+26.1%
0.00%0.0%
Q2 2018$877,000
+217.8%
168,622
+144.4%
0.00%
+100.0%
Q1 2018$276,000
+36.0%
68,995
+131.7%
0.00%
+100.0%
Q4 2017$203,000
+4.6%
29,780
+24.2%
0.00%0.0%
Q3 2017$194,000
+48.1%
23,985
+37.2%
0.00%0.0%
Q2 2017$131,00017,4850.00%
Other shareholders
CIDARA THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
INTERWEST VENTURE MANAGEMENT CO 1,356,813$3,189,0004.48%
Omega Fund Management, LLC 1,508,794$3,546,0002.63%
ALETHEA CAPITAL MANAGEMENT, LLC 482,357$1,134,0001.65%
Opaleye Management Inc. 1,200,000$2,820,0001.05%
BVF INC/IL 2,904,684$6,826,0000.89%
FRAZIER MANAGEMENT LLC 1,312,258$3,084,0000.80%
Monashee Investment Management LLC 480,851$1,130,0000.76%
Aisling Capital LLC 1,021,148$2,400,0000.68%
Trellus Management Company, LLC 94,143$221,0000.50%
Prosight Management, LP 245,764$578,0000.30%
View complete list of CIDARA THERAPEUTICS INC shareholders